Corticosteroids, Plasmapheresis, Argatroban, Rituximab, and Sirolimus Provided Clinical Benefit for Catastrophic Antiphospholipid Syndrome in a Patient with a History of Heparin-Induced Thrombocytopenia
暂无分享,去创建一个
[1] C. Jurcut,et al. Successful Treatment of Catastrophic Antiphospholipid Syndrome Using Rituximab: Case Report and Review of the Literature , 2021, Medicina.
[2] S. Sciascia,et al. Antiphospholipid syndrome: the need for new international classification criteria , 2021, Expert review of clinical immunology.
[3] J. Procházková,et al. Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review , 2021, Biomedicines.
[4] Maryam Khaleel,et al. Blood apheresis technologies – a critical review on challenges towards efficient blood separation and treatment , 2021, Materials Advances.
[5] S. Levine,et al. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria , 2020, Arthritis care & research.
[6] D. D'cruz,et al. An update on the management of antiphospholipid syndrome , 2020, Therapeutic advances in musculoskeletal disease.
[7] D. Erkan,et al. Is there a role for immunosuppression in antiphospholipid syndrome? , 2019, Hematology. American Society of Hematology. Education Program.
[8] G. Canaud,et al. mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] O. Boyman,et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders , 2019, Front. Immunol..
[10] N. Dunbar,et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue , 2019, Journal of clinical apheresis.
[11] E. Rosser,et al. B Cells as a Therapeutic Target in Paediatric Rheumatic Disease , 2019, Front. Immunol..
[12] P. Musette,et al. B Cell Modulation Strategies in Autoimmune Diseases: New Concepts , 2018, Front. Immunol..
[13] S. Knight,et al. A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. , 2017, Transplantation reviews.
[14] D. Erkan,et al. Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease , 2013, Therapeutic advances in musculoskeletal disease.
[15] Y. Shoenfeld,et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. , 2013, Autoimmunity reviews.
[16] R. Cervera. CAPS Registry , 2012, Lupus.
[17] T. Ortel,et al. Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.
[18] D. Keskin,et al. A review of the current use of rituximab in autoimmune diseases. , 2009, International immunopharmacology.
[19] G. Espinosa,et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. , 2006, Arthritis and rheumatism.
[20] Y. Shoenfeld,et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.
[21] Y. Shoenfeld,et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines , 2003, Lupus.
[22] J. Piette,et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. , 2002, Arthritis and rheumatism.
[23] K. Schulz,et al. Descriptive studies: what they can and cannot do , 2002, The Lancet.
[24] M. Brecher. Plasma exchange: Why we do what we do , 2002, Journal of clinical apheresis.